Category: Uncategorized
— asia pr news @ 3:57 pm — 
November 30, 2007PHILADELPHIA, Nov. 30 /PRNewswire-AsiaNet/ –
Novartis Leads the Drug List With its Alzheimer’s Disease Treatment Exelon TDS
Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC)
and leading provider of information solutions to the worldwide research and
business communities, has issued its quarterly The Ones-to-Watch report. It
provides expert insight into the five most promising drugs entering each new
phase of clinical development between July and September 2007.
"Bookending this quarter’s list are three potential treatments for
Alzheimer’s disease, two of which are just entering clinical trials and one
that has already received FDA approval," said Peter Robins, editorial and
content manager, Thomson Scientific. "This quarter’s The Ones to Watch report
showcases the ongoing drive to find therapies for diseases that impact on
ageing and sedentary populations."
Which are the Ones-to-Watch this Quarter?
Topping this quarter’s approval list is Exelon TDS, a new transdermal patch
formulation of rivastigmine, which looks like a winner for Novartis. In the
seven years since its launch, the oral formulation of rivastigmine has seen
year-on-year US dollar growth as a treatment of Alzheimer’s disease- and
Parkinson’s disease-associated dementia. The FDA approved Exelon TDS for mild
to moderate dementia in July 2007. The EU approval followed two months later.
The U.S. launch is expected imminently.
Second on the list is AZOR, which was developed by Daiichi Sankyo for the
treatment of hypertension and includes a combination of two component drugs. In
previous Phase III trials, all doses of the combination produced greater mean
reductions in blood pressure than either drug alone. This, along with its
favorable side-effect profile, should make AZOR an attractive treatment option
for patients whose blood pressure does not respond to either component drug in
isolation. U.S. approval was granted in September 2007.
While the reason for menopause remains unknown, KV Pharmaceutical believes
EvaMist, which takes the third spot on the list, may offer significant
advantages to women experiencing menopause. This product is a small,
easy-to-use hand-held applicator that delivers a pre-set metered dose via the
skin, releasing estradoil into the bloodstream over 24 hours. EvaMist gained
FDA approval in July 2007.
The first of two potential treatments for cancer on the list of notable
drugs gaining approval this quarter is Yondelis, developed by PharmaMar for
patients who have not responded to previous regimens in their treatment of soft
tissue sarcoma. Yondelis is the first approved product from PharmaMar, a
Spanish biotech specializing in cancer drugs derived from marine organisms and
has Orphan Drug status in both the EU and U.S., securing extended protection
against generic competition.
The second approval win for Novartis this quarter, Tasigna, is an orally
available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine
kinases for the potential treatment of various types of leukemia. Though the
drug has been approved only in Switzerland for chronic myeloid leukemia, it is
awaiting approval in the U.S. and Japan and has been recommended for approval
across the EU.
Following are the top five drugs in each category of phase changes:
The Five Most Promising Drugs Entering Phase III Trials
— bevasiranib sodium, (Wet AMD), Opko
— recombinant active glucocerebrosidase, (Gaucher’s disease), Protalix
— odanacatib, (osteoporosis), Merck & Co
— laquinimod, (multiple sclerosis), Active Biotech/Teva
— elesclomol, (solid tumors), Synta
The Five Most Promising Drugs Entering Phase II Trials
— CPP-109, (addiction to cocaine and methamphetamine), Catalyst
Pharmaceuticals
— intranasal insulin formulation, (diabetes), Nastech
— LCP-AtorFen, (cholesterol), Life Cycle
— EC-145, (ovarian and lung cancer), Endocyte
— TG-100801, (AMD, diabetic macular edemia, diabetic retinopathy),
TargeGen
The Five Most Promising Drugs Entering Phase I Trials
— affitope AD-01, (Alzheimer’s disease), AFFiRiS
— MEM-63908, (Alzheimer’s disease, CNS disorders), Memory/Roche
— TC-5619, (schizophrenia, depression), Targacept
— RDEA-806, (HIV infection), Ardea Biosciences
— APD-791, (arterial thrombosis), Arena Pharmaceuticals
About This Quarterly Report:
Data for this report was compiled and analyzed using Thomson Pharma(R), a
comprehensive global pharmaceutical information solution that covers the entire
drug discovery and development pipeline. Its competitive intelligence and
strategic data can justify and speed decision-making, facilitate more focused
collaboration, and encourage innovation.
For a copy of the full report with analysis, visit:
http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/tp_qr_jul-sep2007.pdf
About The Thomson Corporation
The Thomson Corporation (www.thomson.com) is a global leader in providing
essential electronic workflow solutions to business and professional
customers. With operational headquarters in Stamford, CT, Thomson provides
value-added information, software tools and applications to professionals in
the fields of law, tax, accounting, financial services, scientific research,
and healthcare. The corporation’s common shares are listed on the New York and
Toronto stock exchanges (NYSE: TOC; TSX: TOC).
Thomson Scientific is a business of The Thomson Corporation. Its
information solutions assist professionals at every stage of research and
development — from discovery to analysis to product development and
distribution. Thomson Scientific information solutions can be found at
scientific.thomson.com.
Contact:
Eoin Bedford
Thomson Scientific
+44 207 433 4691
eoin.bedford@thomson.com
SOURCE: Thomson Scientific
CONTACT: Eoin Bedford of Thomson Scientific, +44-207-433-4691,
eoin.bedford@thomson.com/
Web site: http://www.scientific.thomson.com /
(TOC TOC.)
Sorry, comments are closed.